Cassava Sciences Inc vs Oracle Corporation — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Oracle Corporation trades at $148.95 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 8775.9× Cassava Sciences Inc's market cap, and Oracle Corporation pays a 1.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ORCL | |
|---|---|---|
Market Cap | $47.75M | $419.05B |
Sector | Health | Technology |
52-Week High | $4.64 | $328.33 |
52-Week Low | $0.87 | $114.99 |
Enterprise Value | -$34.93M | $548.30B |
Dividend Yield | — | 1.37% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.
Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →